Phase 4 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older.
- Before your heart procedure, a heart scan (echocardiogram) showed that your heart's pumping strength was 40% or below.
- You have successfully had surgery or a procedure to fix a treatable heart problem, such as heart valve surgery (mitral, aortic, or tricuspid valve), a minimally invasive valve replacement (TAVI), or a procedure to restore blood flow to the heart (bypass surgery or stenting).
- You joined the study either up to 3 months before your corrective procedure or within 10 days after it.
- After your procedure, your condition is stable, meaning your blood pressure is adequate, your heart rate is in a normal range (50–110 beats per minute), you are not on drips for your heart or fluid removal, and you show no signs of fluid build-up.
- If you were already taking certain heart medications called ARNI or SGLT2 inhibitors, you must stop taking them for at least one week before joining the trial.
- You must be willing and able to sign a consent form agreeing to take part.
Who may not be able to join:
- You have a history of serious abnormal heart rhythms (sustained ventricular tachycardia or ventricular fibrillation).
- After your valve surgery, there is more than a moderate amount of blood leaking around or through the valve.
- If you had a procedure to restore blood flow to your heart, there are still significant blockages remaining in your heart arteries.
- After bypass surgery, a scan has shown that one of the new grafts is blocked.
- You are planning to become pregnant during the study period.
- Your blood pressure remains too high (above 160 mmHg) even with medication.
- Your kidneys are not working well enough, based on a blood test that measures kidney filtering ability (confirm with trial site).
- You are unable to tolerate a specific combination heart medication called sacubitril/valsartan, for example due to low blood pressure, a history of severe allergic swelling (angioedema), or a certain type of kidney artery narrowing.
- You are unable to tolerate a type of diabetes medication called SGLT2 inhibitors — for example, if you have type 1 diabetes or have had repeated episodes of a serious condition called diabetic ketoacidosis.
- You have any other health condition that the study doctor feels would make it difficult for you to safely participate or be followed up during the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kyungsub Song, MD, Keimyung University Dongsan Medical Center
Phone: 82)053-258-7307
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in left ventricular ejection fraction (LVEF) at 12 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.